PFE Stock Risk & Deep Value Analysis
Pfizer Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About PFE Stock
We analyzed Pfizer Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PFE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
PFE Risk Analysis & Red Flags
What Could Go Wrong
Pfizer faces significant pressure to offset declining COVID-19 product sales and substantial revenue loss from upcoming patent expirations (LOEs). If new pipeline drugs fail to deliver expected sales growth or cost-cutting initiatives do not fully materialize, coupled with potential adverse legal outcomes, the company's revenue and earnings could continue to contract, leading to further investor skepticism and stock price erosion.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
FY2026 revenue and EPS guidance projects declines (7.5% YoY EPS decline expected for FY2026).
- ⚠
FCF payout ratio for dividends exceeds 100% (FY2025 FCF $9.076B vs. dividends $9.771B).
- ⚠
Ongoing Moderna patent lawsuit regarding mRNA vaccine technology.
- ⚠
Mixed efficacy results for key pipeline asset (Lyme vaccine, 73-75% efficacy, primary endpoint not fully met).
Upcoming Risk Events
- 📅
Q1 2026 earnings miss or downward revision of FY2026 guidance
- 📅
Adverse ruling or significant financial penalty in Moderna patent lawsuit
- 📅
Further setbacks in key pipeline drug development or regulatory approvals
- 📅
Accelerated impact from Inflation Reduction Act (IRA) drug price negotiations
When to Reconsider
- 🚪
Exit if Q1 2026 earnings or subsequent guidance shows significant acceleration in revenue/EPS decline or further LOE impact.
- 🚪
Sell if free cash flow consistently remains below dividend payout for multiple quarters, indicating unsustainability.
- 🚪
Exit if the Moderna patent lawsuit results in a substantial negative judgment or injunction affecting mRNA product sales.
Unlock PFE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Pfizer Inc (PFE) Do?
Market Cap
$154.61B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
81,000
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Visit Pfizer Inc WebsiteInvestment Thesis
Pfizer is a mature pharmaceutical powerhouse with a consistent dividend and robust R&D capabilities, but it is currently navigating significant revenue and earnings headwinds from declining COVID-19 product sales and upcoming patent expirations. While strategic cost-cutting and a diverse pipeline offer long-term stability, the company's sheer size and industry dynamics make a 10x growth potential within 3-5 years highly unrealistic. It's best suited as a conservative income play rather than a speculative growth investment.
Is PFE Stock Undervalued?
Unlock the full AI analysis for PFE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PFE Price Targets & Strategy
12-Month Target
$29.80
Bull Case
$35.00
Bear Case
$24.00
Valuation Basis
10x forward P/E applied to consensus FY2026 EPS of $2.98.
Entry Strategy
Consider dollar-cost averaging near current levels ($27-$28), potentially looking for dips towards recent support zones if identifiable. UBS target is $27, suggesting current price is fair value.
Exit Strategy
Take profit on any significant rallies towards $32-$35 (potential 15-25% upside). Implement a stop loss below the recent low, e.g., $25, to limit downside risk.
Portfolio Allocation
1-3% for conservative investors seeking income, not suitable for aggressive growth-oriented portfolios.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PFE Financially Healthy?
Valuation
P/E Ratio
19.90
Forward P/E
8.73
EV/EBITDA
9.11
PEG Ratio
0.87
Price/Book
1.78
Price/Sales
2.26
Profitability
Gross Margin
75.81%
Operating Margin
15.43%
Net Margin
12.42%
Return on Equity
8.68%
Revenue Growth
-1.64%
EPS
$1.36
Balance Sheet
Current Ratio
1.16
Quick Ratio
0.87
Debt/Equity
0.75
Total Debt
$47.90B
Cash & Equivalents
$8.90B
Cash Flow
Operating Cash Flow
$5.30B
Free Cash Flow
$8.52B
EBITDA
$7.75B
Other
Beta (Volatility)
0.34
Dividend Yield
6.34%
Does PFE Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable (but constantly challenged by patent cliffs)
Moat Sources
3 Identified
Pfizer's wide moat is durable due to its vast portfolio of patented drugs, continuous R&D, and global scale allowing efficient drug development and distribution. However, the cyclical nature of patent expirations necessitates constant innovation to replenish the pipeline and maintain market share, which acts as a 'treadmill effect' on profitability.
Moat Erosion Risks
- •Expiration of key drug patents (Loss of Exclusivity - LOE), leading to competition from generics and biosimilars (e.g., Eliquis, Prevnar, Vyndaqel 2026-2030).
- •Increasing regulatory scrutiny and price negotiation pressure, particularly from government initiatives like the Inflation Reduction Act.
- •Failure of pipeline drugs to gain regulatory approval or achieve blockbuster sales to offset LOE impacts.
PFE Competitive Moat Analysis
Sign up to see competitive advantages
PFE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Large-cap pharma typically attracts less 'social media buzz' for explosive growth, more for stability/dividends).
Institutional Sentiment
Neutral (UBS raised PT but maintained Neutral rating, indicating cautious outlook rather than strong conviction).
Insider Activity (Form 4)
CEO Albert Bourla was granted 21 cash-settled Phantom Stock Units ($589.68 value) on March 31, 2026. SVP Dennis P. Hancock reported initial ownership of 45,097 shares direct + SARs. No significant direct open market buys or sells by executives in the last 90 days were reported, indicating no strong bullish or bearish conviction from insider trading.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
2026-05-05
Surprise Probability
Medium
Historical Earnings Pattern
Pfizer's stock typically exhibits moderate reactions to earnings reports unless there is a significant surprise in forward guidance, major pipeline news, or an unexpected shift in patent cliff projections. Recent reactions have been muted or negative given the declining revenue trajectory.
Key Metrics to Watch
Competitive Position
Top Competitor
Merck (MRK)
Market Share Trend
Stable across most legacy therapeutic areas but facing erosion due to biosimilars/generics; COVID vaccine market share is declining significantly. Aiming for gains in new areas like oncology via acquisitions (e.g., Seagen).
Valuation vs Peers
Pfizer's trailing P/E of 20.04 (as of Apr 14, 2026) is in line or potentially slightly above peers facing similar revenue declines and patent expirations. Growth-oriented biotech/pharma often trade at higher multiples.
Competitive Advantages
- •Broad, diversified product portfolio and pipeline across multiple therapeutic areas.
- •Extensive global manufacturing, distribution, and commercialization capabilities.
- •Strong brand recognition and established relationships with healthcare systems and governments.
- •Significant R&D investment capacity to develop new patented drugs.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PFE Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 5, 2026)
- •Regulatory updates on Lyme vaccine (following mixed Phase 3 results)
- •Progress on mRNA flu/COVID combination vaccine Phase 3 trials
Medium-Term (6-18 months)
- •Realization of $4B cost savings by end of 2025 (as announced previously)
- •Resolution or progress in Moderna patent lawsuit (filed 2022)
- •Pipeline advancements for non-COVID assets
Long-Term (18+ months)
- •Successful navigation of key patent expirations (Eliquis, Prevnar, Vyndaqel 2026-2030)
- •Diversification of revenue streams post-COVID product decline
- •Strategic M&A for pipeline enhancement
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PFE?
- ✓
Sustained acceleration in non-COVID operational revenue growth above 5% per annum.
- ✓
Free cash flow consistently exceeding dividend payout by a significant margin.
- ✓
Approval and successful commercialization of a major blockbuster drug with multi-billion dollar peak sales potential.
- ✓
Favorable resolution of the Moderna patent lawsuit without significant financial impact.
Bull Case Analysis
See what could go right with Premium
Competing with PFE
See how Pfizer Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Pfizer Inc Makes Money
Pfizer is a leading global biopharmaceutical company that discovers, develops, manufactures, markets, and sells prescription medicines and vaccines across a broad range of therapeutic areas. It primarily generates revenue by selling patented drugs and vaccines through its global sales force to wholesalers, retailers, hospitals, clinics, governments, and individual provider offices. The company's core strategy involves continuous investment in research and development to bring innovative, high-value treatments to market, thereby replenishing its product portfolio and offsetting revenue losses from existing drugs that lose patent protection.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Pfizer Inc (PFE)?
As of April 15, 2026, Pfizer Inc has a DVR Score of 0.2 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Pfizer Inc?
Pfizer Inc's market capitalization is approximately $154.6B. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does Pfizer Inc use?
PFE is the ticker symbol for Pfizer Inc. The company trades on the NYQ.
What is the risk level for PFE stock?
Our analysis rates Pfizer Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PFE?
Pfizer Inc currently has a price-to-earnings (P/E) ratio of 19.9. This is in line with broader market averages.
Does Pfizer Inc pay a dividend?
Yes, Pfizer Inc pays a dividend with a current yield of approximately 6.34%.
Is Pfizer Inc's revenue growing?
Pfizer Inc has reported revenue growth of -1.6%. Revenue has been declining, which warrants closer examination.
Is PFE stock profitable?
Pfizer Inc has a profit margin of 12.4%. The company is profitable but margins are modest.
How often is the PFE DVR analysis updated?
Our AI-powered analysis of Pfizer Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PFE (Pfizer Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.